Bausch & Lomb
This article was originally published in The Gray Sheet
Executive Summary
Investment banking firm Warburg Dillon Reed has been retained to assist in the process of evaluating strategic options for its lagging sunglass business - which includes the Ray-Ban and Killer Loop lines. "Alternatives to be considered include joint ventures, sale, spin-off, or other business combinations," the firm states in a Nov. 18 release. B&L plans to focus on leveraging its three eye-related healthcare businesses - Vision Care, Pharmaceuticals and Surgical Products. Despite recent improvements in the eyewear business, "it is apparent to us that [B&L's] greatest potential for accelerated growth in the future lies in our healthcare business for the eyes," states William Carpenter, B&L president and CEO. Eyewear business sales were down 6.3% in fiscal 1997 (ended Dec. 27) to $492.1 mil. while corporate revenues from ongoing product lines were up 2% to $1.9 bil
You may also be interested in...
Fujifilm Demonstrates Health Specialism With European HealthTech Spinout
From X-ray film in 1936 to the world’s first digital X-ray system in 1983, Fujifilm has a long heritage in medical diagnostics.
Financing Quarterly Statistics, Q1 2024
During Q1, biopharmas brought in an aggregate $30.1bn in financing and device company fundraising totaled $2.8bn; while in vitro diagnostic firms and research tools players raised $724m.
Helping Organizations Deliver On KPIs And Giving Staff A Voice
ImproveWell has won awards for its software technology that allows health care staff at the sharp end of patient care to report on problems as they happen. The outcome is a real-time learning process that contributes to improved operational efficiencies for health systems, says In Vivo Rising Leader Lara Mott.